Shane W. O’Brien

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 347 citations · Full text

Medicine, Oncology, Pharmacology +7

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Yifan Wang, Andrea J. Bernhardy, Cristina Cruz et al. · Cancer Research · 2016 · 271 citations · Full text

Medicine, Genetics, Oncology +16

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer

Alison Kurimchak, Claude Shelton, Kelly Duncan et al. · Cell Reports · 2016 · 201 citations · Full text

Medicine, Oncology, Pharmacology +17

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target

Alfredo Perales‐Puchalt, Nikolaos Svoronos, Melanie R. Rutkowski et al. · Clinical Cancer Research · 2016 · 119 citations

Medicine, Immunology, Oncology +17

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion

T-V Do, Fang Xiao, L. Bickel et al. · Oncogene · 2013 · 115 citations

Life Sciences, Cell Biology, Molecular Biology +10